Seer, Inc. (NASDAQ: SEER) received a second, improved unsolicited acquisition proposal from the Radoff‑JEC Group on April 24, 2026. The new offer values the company at $2.35 per share in cash and includes a contingent value right (CVR) that would entitle shareholders to 80 % of the net proceeds from any future sale or disposition of Seer’s business and assets. The Radoff‑JEC Group currently holds roughly 7.6 % of Seer’s outstanding shares.
The $2.35 cash price represents a 39 % premium, but the premium is calculated against Seer’s unaffected closing price on April 10, 2026, not the closing price on the announcement date. This distinction corrects the earlier misstatement that the premium was based on the April 24 close.
The proposal improves on the group’s earlier April 13 offer of $2.25 per share, raising the cash component by $0.10 and providing a more favorable CVR structure. The Radoff‑JEC Group’s letter to Seer’s board, received on April 24, requests a response by May 2, 2026.
Seer’s financial performance has been a key focus of the activist group’s criticism. The company reported revenue of $16.6 million in 2025, only modestly above $15.5 million in 2022, and has accumulated cumulative losses exceeding $465 million. The group has highlighted stagnant revenue growth and margin compression as evidence that Seer has not delivered on its growth promises since its IPO.
The lack of revenue growth is attributed to intense competitive pressure in the proteomics and life‑science market, where peers such as Alamar Biosciences have achieved higher growth rates with lower capital intensity. Seer’s business mix has not shifted toward higher‑margin segments, and the company has not demonstrated a clear path to scale its product portfolio or expand its customer base.
The CVR is contingent on Seer closing with at least $215 million of net cash and cash equivalents. If a future sale or disposition occurs, shareholders would receive 80 % of the net proceeds, providing a potential upside beyond the immediate cash offer.
In response to the proposal, Seer’s board has activated a defensive “poison pill” (Tax Benefit Preservation Plan) and is preparing to address the Radoff‑JEC Group’s proxy contest, which seeks to replace the board with nominees aligned with the activist group’s strategy.
Market reaction to the improved offer was positive: pre‑market trading on April 24 showed a 3.6 % lift, following a 13.61 % jump on the day of the earlier April 13 proposal. Investors have responded to the premium and the CVR, viewing the offer as a potential catalyst for unlocking shareholder value amid concerns about Seer’s operational performance.
The acquisition proposal signals a possible change of control for Seer and could prompt a strategic pivot or sale of assets. The activist group’s dual strategy—offering a takeover bid while launching a proxy contest—underscores its intent to reshape the company’s governance and business direction. For Seer’s shareholders, the proposal presents an immediate cash option and a potential future upside through the CVR, while the board must weigh the offer against the company’s long‑term growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.